Table 1.
Antibiotic resistance in patients with resistant E. cloacae and susceptible E. cloacae
| Antibiotic (combination) | Susceptible E. cloacae (n = 2075 unique patients, 3030 isolates) | Multi-resistant E. cloacae (n = 373 patients, 1373 isolates) | Selected for WGS (n = 112 isolates) | ||
|---|---|---|---|---|---|
| Patients (n) tested | % non-susceptible / positivea | Patients (n) tested | % non- susceptible / positivea | % non- susceptible / positivea | |
| ciprofloxacin | 2075 | 1.3 | 373 | 42.9 | 28.6 |
| colistin | 1122 | 0 | 205 | 68.8 | 78.4b |
| gentamicin | 2075 | 0.2 | 373 | 82.8 | 86.6 |
| imipenem | 2070 | 0.2 | 373 | 5.6 | 6.3 |
| meropenem | 2073 | 0.1 | 373 | 4.8 | 6.3 |
| tobramycin | 2075 | 0 | 373 | 89.3 | 87.5 |
| trimethoprim/ sulfamethoxazole | 2075 | 5.5 | 373 | 34.6 | 86.6 |
| ESBL production | 873 | 0 | 156 | 71.2 | 72.3 |
| CIP or SXT | 2075 | 0.6 | 373 | 17.7 | 5.4 |
| CIP or SXT or MEM | 2064 | 0 | 349 | 0.9 | 0 |
| CIP or SXT or MEM or CST | 1118 | 0 | 187 | 0.5 | 0 |
CIP ciprofloxacin, CST colistin, ESBL extended-spectrum beta-lactamase, MEM meropenem, n number, SXT trimethoprim/ sulfamethoxazole, WGS whole-genome sequencing
a% non-susceptible for antibiotics or % ESBL positive
b111/112 isolates tested
Number of resistant E. cloacae isolates tested: ciprofloxacin: n = 1373, colistin: n = 784, gentamicin: n = 1373, imipenem: n = 1373, meropenem: n = 1371, tobramycin: n = 1373, trimethoprim/ sulfamethoxazole: n = 1372. Number of susceptible E. cloacae isolates tested: ciprofloxacin: n = 3030, colistin: n = 1613, gentamicin: n = 3030, imipenem: n = 3024, meropenem: n = 3028, tobramycin: n = 3030, trimethoprim/ sulfamethoxazole: n = 3030